Editing CSL Limited (section)

=== Acquisition of ZLB Bioplasma AG and Aventis Behring ===
In 2000, CSL doubled its size through the purchase of a Swiss plasma company, the Bern-based ZLB Bioplasma AG.<ref name="wsj-csl-buys-zlb-bio">{{cite news |author1=Dow Jones Newswires |title=Australia's CSL Agrees to Acquire Aventis Unit for up to $925 Million |url=https://www.wsj.com/articles/SB107095001643104600 |access-date=22 February 2021 |work=The Wall Street Journal |date=9 December 2003 |quote=''… this deal eclipses the A$1 billion (US$740.2 million) CSL spent in 2000 to buy ZLB Bioplasma from the Swiss Red Cross.''}}</ref> In 2004, during a period of plasma oversupply, the company expanded again with the purchase of the German medical company Aventis Behring.<ref name="pharma-letr-csl-buys-avent-behr">{{cite web |title=Aventis disposes of Behring unit with $925M sale to Australia's CSL – |url=https://www.thepharmaletter.com/article/aventis-disposes-of-behring-unit-with-925m-sale-to-australia-s-csl |website=thepharmaletter.com |publisher=The Pharma Letter |access-date=22 February 2021 |date=15 December 2003 |quote=''… Aventis says that it has agreed to sell its Aventis Behring blood products business to Australia's CSL …'' |url-status=live|archive-url=https://web.archive.org/web/20210923070545/https://www.thepharmaletter.com/article/aventis-disposes-of-behring-unit-with-925m-sale-to-australia-s-csl |archive-date=23 September 2021 }}</ref> The company was the second Australian public company to have reached a share price of over $100 per share.<ref name="quest-csl-$100+">{{cite web |title=CSL bursts through the $100 barrier |url=https://questap.com.au/csl-bursts-through-the-100-barrier/ |publisher=Quest Asset Partners |date= 4 August 2015 |access-date=22 February 2021 |url-status=live|archive-url=https://web.archive.org/web/20160228082802/http://questap.com.au/csl-bursts-through-the-100-barrier/ |archive-date=28 February 2016 }}</ref>